Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

NewsGuard 100/100 Score

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine.

The study caps two years of investigation based on research showing PRP could promote progressive improvement and even repair for painful conditions such as elbow tendonitis and "tennis elbow." The research team from Stony Brook, N.Y., investigated whether PRP might also prove an effective alternative to corticosteroid injection or radiofrequency ablation for cervical and lumbar facet arthropathy. Arthropathy is a collective term for joint disease that can encompass many types of specific and non-specific pathologies or injuries and affects all age groups.

"It was our hope, based on other indications, that we might actually heal a joint," or observe long-term (up to a year) improvement, said Marco Palmieri, D.O., the lead study author, who specializes in interventional techniques in the Chronic Pain Division of the Center For Pain Management At Stony Brook. "Unfortunately, we haven't seen that in our results."

Palmieri stressed, however, that the treatment has promise, and further work should focus on identifying proper treatment protocols and subgroups that might benefit most from the therapy.

The researchers examined pain and functional outcomes for 24 PRP patients, extracted from medical records with institutional review board approval. They found that pain intensity levels decreased in months one and three compared to baseline (p≤0.01) but returned to baseline in months six and 12. Similarly, measures of function and disability decreased in the first month (both p<0.01) but returned to baseline afterward.

Behavioral markers measured by PROMIS tools, developed through the National Institutes of Health, found less anger, anxiety, pain interference and pain behavior in the first month (all p≤0.03). The patients also reported higher physical function and satisfaction with social roles (p≤0.03) in the first and third months.

Palmieri said part of the follow-up research would entail determining the optimal intervals between injections and other particulars that have not been clearly delineated to date.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the ‘immune self,’ and how can this concept benefit immunological research?